Clinical Trial Update: Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating 0.05% CsA and 0.1% FK506 eye drops for ocular graft-versus-host disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Versus Host Disease in Eye

Drugs mentioned

• 0.05% CsA eye drops (cyclosporine)
• 0.1% FK506 eye drops (tacrolimus)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Graft Versus Host Disease in Eye | Phase 4 | Status: COMPLETED